Immunogenicity 15601

summary
Sample ID
4095
Response
Negative
Tumor Type
Colorectal cancer
Gene Symbol
RSAD2 (FPKM: 9.32)
Transcript ID
NM_080657
HLA INFO
A*03:01
TCR INFO

No TCR info found!

T cell Tumor cell A*03:01
sequence
Full length protein sequence (361 aa)
MWVLT
1
PAAFA
6
GKLLS
11
VFRQP
16
LSSLW
21
RSLVP
26
LFCWL
31
RATFW
36
LLATK
41
RRKQQ
46
LVLRG
51
PDETK
56
EEEED
61
PPLPT
66
TPTSV
71
NYHFT
76
RQCNY
81
KCGFC
86
FHTAK
91
TSFVL
96
PLEEA
101
KRGLL
106
LLKEA
111
GMEKI
116
NFSGG
121
EPFLQ
126
DRGEY
131
LGKLV
136
RFCKV
141
ELRLP
146
SVSIV
151
SNGSL
156
IRERW
161
FQNYG
166
EYLDI
171
LAISC
176
DSFDE
181
EVNVL
186
IGRGQ
191
GKKNH
196
VENLQ
201
KLRRW
206
CRDYR
211
VAFKI
216
NSVIN
221
RFNVE
226
EDMTE
231
QIKAL
236
NPVRW
241
KVFQC
246
LLIEG
251
ENCGE
256
DALRE
261
AERFV
266
IGDEE
271
FERFL
276
ERHKE
281
VSCLV
286
PESNQ
291
KMKDS
296
YLILD
301
EYMRF
306
LNCRK
311
GRKDP
316
SKSIL
321
DVGVE
326
EAIKF
331
SGFDE
336
KMFLK
341
RGGKY
346
IWSKA
351
DLKLD
356
W
361
Mutation Information
DNA mutation:
c.C744A
Peptide Range:
236 ~ 260
Mut AA position:
248 (13 in Wild Type peptide)
Alignment
Wild Type:
"QIKALNPVRWKVFQCLLIEGENCGE
||||||||||||.||||||||||||
Mutant:
QIKALNPVRWKVLQCLLIEGENCGE"
reference

N Engl J Med, 2016

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Gene Name (from Reference) RSAD2

clinic trial
Checkpoint Blockade

None

ACT

None

Vaccination

None

Curative Effect

None

experiment
minimal_peptide

None

Antigen Type

TMG RNA

T-cell Source

TILs

APC Type

DCs

Assay

IFNg ELISPOT assay